Biotechnology company Altimmune Inc. reported Friday that its experimental drug for a serious form of fatty liver disease showed promising results in a mid-stage clinical study, with improvements in liver health markers and patient weight after 48 weeks of treatment.
The study focused on metabolic dysfunction-associated steatohepatitis (MASH) — a progressive liver disease characterized by fat buildup and inflammation that can lead to scarring and liver damage. Altimmune’s drug candidate, pemvidutide, is being evaluated as a potential treatment for this condition.
Study Results After 48 Weeks
After nearly a year of treatment, patients receiving pemvidutide showed improvements in non-invasive tests that assess liver scarring and liver health compared with baseline measurements. These include reductions in liver fat and indicators of inflammation, according to Altimmune’s data.
In addition to liver health measures, people on the 1.8 mg dose of pemvidutide experienced an average 7.5 % body weight loss by week 48, compared with roughly 0.2 % in the placebo group.
Investor Reaction and Challenges Ahead
Despite the favorable signals, some investors reacted cautiously. Because the recent results were based on non-invasive tests rather than biopsy-confirmed findings, market analysts said that biopsy-based outcomes will likely remain a key requirement for regulatory approval in future late-stage trials. As a result, Altimmune’s shares slumped more than 20 % on the news.
Altimmune plans to start a late-stage Phase 3 study next year, including a higher 2.4 mg dose of pemvidutide to further assess its therapeutic potential.
Market Context & Competitive Landscape
Pemvidutide belongs to a class of drugs related to widely used GLP-1 agonists — similar to those in treatments like Novo Nordisk’s Wegovy and Eli Lilly’s Mounjaro — which have shown benefits for weight loss and metabolic conditions in recent years.
While multiple therapies are in development for fatty liver disease, few have yet achieved broad regulatory approval, making the market for effective MASH treatments both medically important and commercially attractive.
